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Abstract Polycystic ovary syndrome (PCOS) is the most
frequent endocrine disorder in women of reproductive age.
In 2006 the Japanese Society of Obstetrics and Gynecology
(JSOG) proposed new, revised diagnostic criteria that in
the future could also be valued internationally. Based on
the new diagnostic criteria, the JSOG has also proposed the
revised treatment criteria in 2008. In PCOS obese patients
desiring children, weight loss and exercise is recom-
mended. Nonobese patients, or those obese women who do
not ovulate after lifestyle changes, are submitted to ovu-
lation-induction therapy with clomiphene citrate (CC).
Obese CC-resistant patients who have impaired glucose
tolerance or insulin resistance are treated with a combi-
nation of metformin and CC. If these treatments options are
unsuccessful, ovulation induction with exogenous gona-
dotropin therapy or laparoscopic ovarian drilling (LOD) is
recommended. A low-dose step-up regimen is recom-
mended with careful monitoring in order to reduce the risk
of ovarian hyperstimulation syndrome (OHSS) and multi-
ple pregnancies. Alternatively, with LOD high successful
pregnancy rates of around 60 % are expected with a low
risk of multiple pregnancies. If ovulation induction is
unsuccessful, IVF-ET treatment is indicated. In high
OHSS-risk patients, systematic embryo freezing and sub-
sequent frozen embryo transfer cycles are recommended.
In nonobese, anovulatory PCOS patients not desiring
children, pharmacological treatments such as Holmstro¨m,
Kaufmann regimens or low-dose oral anticonceptives are
used to induce regular withdrawal bleeding. These
treatments are especially important for preventing endo-
metrial hyperplasia and endometrial cancer. These new
diagnostic and treatment criteria hopefully will contribute
to an improved care of PCOS patients in Japan.
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Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine
disorder occurring in 5–10 % of women in reproductive
age [1]. Hyperandrogenism, chronic anovulation, and
infertility are the main features of this heterogeneous
condition [2]. It affects female reproductive performance as
well as it has effects on female health. It was originally
described in 1935 by Stein IF and Levental ML as a syn-
drome consisting of oligomenorrhea and obesity with
enlarged polycystic ovaries [3]. The diagnosis of PCOS is
based on a combination of clinical, biological, and ultra-
sound criteria that have been used variably to define PCOS
[4, 5]. Diagnosis criteria and PCOS definitions used by
clinicians and researchers are almost as heterogenous as the
syndrome. Currently, PCOS is defined by 2003 Rotterdam
criteria [5], which requires at least two of three features for
diagnosis: chronic anovulation, clinical and/or biochemical
signs of hyperandrogenism, or polycystic ovaries. In Japan,
compared to other countries, the usual clinical presentation
of PCOS is slightly different, with less frequently
encountered cases of hyperandrogenism, therefore estab-
lished European or US guidelines are clinically less useful.
In 2006, the Japanese Society of Obstetrics and Gynecol-
ogy (JSOG) has proposed new, revised diagnostic criteria
that in the future could also be valued internationally [6].
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Clinical data of PCOS in Japan
In 2005, JSOG performed the questionnaire research con-
cerning about the clinical data of PCOS which were
examined by 125 institutes or clinics in Japan. 1498 cases
of ovarian dysfunction were divided into the PCOS group
and the non-PCOS group. Rates of abnormal range of
serum hormone levels in PCOS and the other ovarian
dysfunction in Japan are shown in Fig. 1 [6]. Rates of
abnormal range of androstenedione, LH/FSH and LH in
PCOS were significantly higher than those in the other
anovulation (P \ 0.01). Body mass index (BMI) values
and frequency rates of obesity, DM and hyperlipidemia in
the PCOS group are shown in Fig. 2. BMI values were
23.1 ± 6.0 kg/m2 in PCOS and 21.9 ± 5.8 kg/m2 in non-
PCOS, therefore the former was significantly higher than
the latter (P \ 0.01). Rate of BMI higher than 25 kg/m2 is
25.9 % in PCOS and significantly higher than that of the
other group (P \ 0.01). Figure 3 shows the rate of insulin
resistance of PCOS in Japan. Rate of HOMA-R higher than
2.5 is 32.8 %, and that of HOMA-R lower than 1.6 is
50.1 %. So, rate of high insulin resistance is about 1/3 of
PCOS in Japan. Serum hormone levels and insulin resis-
tance in PCOS are shown in Fig. 4. PCOS with high
HOMA-R (]2.5) shows significantly higher values
(P \ 0.01) of free testosterone and BMI over 25 kg/m2 in
Japan [6].
Clinical feature of PCOS
Diagnostic criteria of PCOS is based on three main fea-
tures: (1) cycle irregularities, (2) polycystic changes in the
ovary by ultrasonography, (3) endocrine anomalies (LH or
androgen hypersecretion). The diagnosis of PCOS was
recently debated and suggestions followed in the Rotter-
dam Consensus statement [5] and in JSOG statement [6].
Figure 5 shows the diagnostic criteria of PCOS in Western
countries and Japan.
Amenorrhea and oligomenorrhea are always present.
Menstrual disturbances are present of obese PCOS and
72 % with lean PCOS. It is estimated that 40 to 60 % of
women with PCOS in Western countries [7, 8] and 26 % of
them in Japan [6] are overweight or obese. Obesity has
Fig. 1 Rate of abnormal range
of serum hormone levels in
PCOS and the other ovarian
dysfunction in Japan. Rates
of abnormal range of
androstenedione, LH/FSH and
LH in PCOS are significantly
higher than those in the other
anovulation [6]
Fig. 2 Obesity, DM and
hyperlipidemia in PCOS; BMI
of PCOS is significantly higher
than that in the other. Rate of
BMI higher than 25 kg/m2 is
25.9 % and significantly higher
than that of the others [6]
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been associated with infertility and an increased risk of
menstrual irregularity or amenorrhea [9]. Transvaginal
sonography (TVS) plays an essential role in diagnosis and
treatment of PCOS. JSOG mentioned criteria for PCO, i.e.,
atypical polycystic pattern was defined by the presence of
10 or more cysts measuring 2–9 mm in diameter in a single
plane arranged peripherally around stroma [6]. TVS has got
important role in diagnosing, monitoring and treatment of
PCOS patients. So careful clinical, biochemical, and TVS
monitoring with tender loving care is required [10].
Endocrine anomalies and insulin resistance in PCOS
Serum hormone levels
Abnormal LH/FSH ratio is the main issue in the continu-
ation of anovulatory state in PCOS subjects. Increased LH
and decreased or normal FSH are due to (a) GnRH pulsatile
secretion, i.e. at hypothalamic level. (b) high estrogen
environment, i.e., at pituitary level [10]. In PCOS, clini-
cally intense androgenization due to excess androgen pro-
duction is observed. Hyperandrogenemia induces the
increase in testosterone, androstenedione, dehydroepian-
drosterone (DHEA), DHEA-S, 17-hydroxyprogesterone
and estrone (E1) (excess androgen converted to E1 by
peripheral fat). Decrease in the sex hormone binding pro-
tein in the liver, increase in insulin response in the ovary
and the effect of high LH, induce the increase in androgen
secretion in the ovary. After that, follicle growth and
maturation are suppressed [5, 6, 11].
Insulin resistance and concomitant hyperinsulinemia
Insulin resistance and concomitant hyperinsulinemia are
frequently found in obese PCOS women [11, 12].
Approximately 50–60 % of PCOS patients suffer from
insulin resistance in Western countries [10] and 33 % in
Japan [6]. Seventy % of obese PCOS and 20 % of thin
PCOS have hyperinsulinemia in Western countries.
Increased insulin resistance causes hyperglycemia leading
to hyperinsulinemia and it amplifies LH action on theca
Fig. 3 HOMA-R, fasting blood
sugar (FBS) and
immunoreactive insulin (IRI) of
PCOS in Japan; Rate of HOMA-
R 2.5 or higher values is
32.8 %. Rate of high insulin
resistance is about 1/3 of PCOS
in Japan [6]. (HOMA-
R = FBS 9 IRI 7 405)
Fig. 4 Serum hormone levels and insulin resistance in PCOS; PCOS
with high HOMA-R shows significantly higher values of free
testosterone and BMI over 25 kg/m2 in Japan [6]
Fig. 5 New criteria of PCOS in Japan and Europe/USA [5, 6]
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cells and again increase in androgen level [10, 13].
Hyperinsulinemia, insulin resistance, and an increase in
androgen production are all linked together in PCOS
patients. It is also known that patients with insulin resis-
tance are often resistant to ovulation induction [10, 12].
New criteria of PCOS treatment in Japan
Based on the above-mentioned diagnostic criteria, the
JSOG has also proposed the revised treatment criteria of
PCOS in 2008 (Fig. 6) [14].
Treatment of PCOS desiring children
Treatment of obesity in PCOS
For obese PCOS patients (BMI ]25 kg/m2), weight loss
and exercise are recommended as a first option. Norman
et al. [15]. demonstrated that lifestyle modification led to
increased insulin sensitivity and resulted in improved
ovulation and fertility in obese women with PCOS. This
approach of lifestyle modification, which includes weight-
reducing diet and exercise, should be the first step in the
management of them [16]. Increase in physical activity and
loss of at least 10 % of body weight are given in the form
of lifestyle modification. Weight reduction causes sponta-
neous ovulation and dose of stimulation of medicine is less
required [17, 18]. Lifestyle management should also be
used as the primary therapy in overweight and obese
women with PCOS for the treatment of metabolic com-
plications [19].
Clomiphene citrate for PCOS
Clomiphene citrate (CC) is the standard drug used for
ovulation induction in women with PCOS [20–24]. Suc-
cessful ovulation is achieved in 70–85 % of them and
40–50 % will conceive [25]. Nonobese patients or those
obese women who do not ovulate after lifestyle changes are
submitted to ovulation induction therapy with CC. CC is
antiestrogenic and it binds with estrogen receptors causing
decreased concentration of receptors. So activation of
GnRH, increase in FSH and/or LH and growth of the
dominant follicle occur. All cycles of CC should be mon-
itored by ultrasound. To prevent ovarian hyperstimulation
syndrome (OHSS), we should have control over the
growing follicle and E2 levels. Hyperandrogenism and
obesity affect the CC response adversely. Failure to ovulate
with 3 months of use of CC 150 mg/day for 5 days is
called CC resistance, and 20 % of PCOS patients will be
CC resistant [10]. In CC resistant PCOS patients with
hirsutism and high androgen concentrations, the combina-
tion of dexamethasone and CC is effective, because
dexamethasone reduces the levels of androgens [26]. In CC
resistant PCOS patients with galactorrhea or hyperprolac-
tinemia, both CC and dopamine agonists should be used
[27].
Combination of metformin and clomiphene citrate(CC)
for PCOS with insulin resistant
Numerous articles have been published where insulin
sensitizers such as biguanides (metformin) [28–30] and
thiazolidinediones (troglitazone) [31] have been used and
proven to improve metabolic abnormalities in PCOS
patients. Metformin declines the peripheral glucose level
without interfering with pancreatic b-cell function [10], by
inhibiting hepatic gluconeogenesis and increasing insulin
receptor affinity. Metformin reduces levels of LH, hyper-
insulinemia and decrease ovarian levels of androgen [32].
Hyperinsulinemic and hyperandrogenic PCOS patients
with thecal hyperplasia are best downregulated with met-
formin. Several trials were prospective double-blind pla-
cebo controlled [33–36]. Each of those trials randomized
metformin with placebo in the CC-resistant patient. In one
trial [35] there was no difference in outcome. The other
trials had a statistically significant improvement when
metformin was added to CC in the CC-resistant patients.
Kurabayashi et al. [37] also reported that combination of
metformin and CC could improved ovulation rates in
CC-resistant infertile Japanese women with PCOS in spite
of no effect of metformin treatment alone. Therefore, obese
CC-resistant PCOS patients who have impaired glucose
tolerance or insulin resistance are treated with a combi-
nation of metformin and CC [38].Fig. 6 New criteria of PCOS treatment in Japan [14]
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Ovulation induction of gonadotropin therapy in PCOS
Ovulation induction with exogenous gonadotropin therapy
is recommended for unsuccessful patients in the previously
mentioned treatments. During ovulation induction, a
chronic, low-dose step-up regimen of FSH-only prepara-
tions is recommended [39, 40] with careful monitoring in
order to reduce the risk of OHSS [41] and multiple preg-
nancies. Purified FSH has a theoretical advantage of
avoiding additional LH in PCOS. It is always better to start
with the smallest dose, and always be watchful on vaginal
ultrasonography for number of follicles stimulated and how
they are growing. But E2 level should always be kept
suitable prior to hCG injection when there is evidence of
multiple follicles [10]. If 4 or more numbers of follicles are
found to be getting ]16 mm diameter, hCG injection
should be canceled [14, 42]. These results demonstrate that
the low-dose step-up regimen for with PCOS is the safest
protocol among the stimulation regimens for reducing
multiple follicular development.
Laparoscopic ovarian drilling (LOD) in PCOS
The history of management of PCOS has been sharp turns
from surgical management to medical therapy and later a
renewed interest in surgery [43]. Gjonnaess proposed that
ovulation was initiated by either stromal destruction or
extensive capsular destruction with discharge of the con-
tents of multiple follicle cysts [44]. At present, LOD is
indicated in clomiphene resistant cases and another
approach of gonadotropin therapy [45]. LOD is an effective
procedure in properly selected cases, because drilling
appears to be equally effective with lesser chances of
multiple pregnancies [45, 46]. In LOD treatment, high
success pregnancy rates of around 60 % are expected after
treatment within 6 months of time with a low risk of
adverse effects in PCOS, and peak pregnancy rate is seen
around 6–9 months after surgery [47].
The exact mechanism of induction of ovulation by
LOD is not understood. This may be attributed to the
improved intraovarian stromal blood flow following the
procedure [43]. Daniell and Miller [48] suggested that
physical opening of subcapsular cysts led to the removal
of androgen-containing follicular fluid from the ovarian
environment, thus lowing the androgen content of ovaries.
The total and free testosterone is decreased to 40–50 % of
the preoperative levels. LH levels also decreased follow-
ing the procedure. Change in FSH levels is less marked
and normal inhibin pulsality is restored. The normaliza-
tion of hormonal relationships leads to recruitment of a
new cohort of follicles and resumption of ovarian func-
tion. These endocrine changes occur rapidly and are
sustained for years [43]. The number of holes to be drilled
depends upon the size of the ovaries and the sonographic
appearance which had been noted during the preoperative
work-up. In moderately enlarged ovaries, about 10–12
holes are sufficient but more may be required in volu-
minous ovaries [43]. Treatment patients when followed
sonographically show spontaneous ovulation or much
more improved sensitivity to CC [45]. Overall LOD is
simple procedure with lots of benefits for fertility pres-
ervation, but it should be judiciously employed with strict
selection protocol.
IVF-ET treatment in PCOS
If ovulation induction is unsuccessful or conception cannot
be accomplished as mentioned above, IVF-ET treatment is
indicated. PCOS has been associated with various negative
effects on ovulation induction and IVF-ET outcomes [49–
54]. During ovarian stimulation for IVF-ET, the low-dose
step-up regimens of pure FSH preparation are used for
women with PCOS to prevent adverse effects [39, 40]. In
order to achieve ovulation in those patients, it needs
ovarian stimulation with more risk for OHSS [41]. In high
OHSS-risk patients, systematic embryo freezing and sub-
sequent frozen embryo transfer cycles are recommended
[49, 55].
In vitro maturation (IVM) of oocyte procedure would be
a best option for PCOS treatment in terms of complete
prevention of OHSS [56]. Since the technology has been
clinically applied, the number of centers undergoing it has
increasing. In IVM procedure, the immature oocytes in
germinal vesicle or metaphase I stage are cultured with
medium, gonadotropins and serum for 24–48 h. About
50–60 % of immature oocytes commonly mature to
metaphase II stage [57]. In order to acquire better outcome,
it is essential to elucidate maturation process of human
oocytes.
Treatment of PCOS not desiring for children
For obese PCOS patients, weight loss and exercise are
recommended [17–19]. In non-obese and anovulatory
patients, pharmacological treatments such as Holmstro¨m,
Kaufmann regimens or low-dose oral anticonceptives are
used to induce regular withdrawal bleeding. Early detection
of PCOS mitigate the risks of endometrial hyperplasia and
cancer [9], which caused by ‘unopposed estrogen’ condi-
tion of PCOS. There are moderate quality data to support
that women with PCOS have a 2.7-fold increased risk for
endometrial cancer [58]. Most endometrial cancers are
known to be well differentiated and have a good prognosis.
These hormone therapies are especially important for pre-
venting endometrial hyperplasia and endometrial cancer
[59].
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Conclusion
New, revised diagnostic criteria and revised treatment
criteria of PCOS reported by JSOG are proposed in this
review. These new criteria hopefully will contribute to an
improved care of PCOS patients in Japan.
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